Beta Bionics, Inc. BBNX
21.51
(0.25)
(1.15%)
as of 25 Sep
- Market cap
- $1.2B
- P/E
- 0.0×
Follow BBNX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (26.16%) | (22.71%) | (346.51%) | (169.86%) |
+7 more TTM periods Free account |
|
| (23.45%) | (20.68%) | (30.60%) | (47.17%) | ||
ROIC |
(68.47%) | (67.46%) | (65.51%) | (64.88%) | |
Return on Tangible Assets |
(33.82%) | (28.28%) | (29.81%) | (30.89%) | |
Average Days of Receivables |
55.37 | 52.15 | 62.32 | 47.55 | |
Free Cash Flow per Share |
(7.59) | (7.60) | (8.22) | (1.39) | |
Free Cash Flow |
(338.15) | (337.86) | (332.96) | (60.53) | |
Capital Expenditures |
(282.34) | (283.08) | (282.03) | (3.95) | |
Piotroski F-Score |
3.00 | 3.00 | 4.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(12.77%) | (11.63%) | (10.05%) | (10.81%) | |
Accounts Receivable Turnover |
8.08 | 8.89 | 6.89 | 11.08 | |
Accounts Payable Turnover |
11.31 | 16.37 | 11.39 | 14.32 | |
Inventory Turnover |
2.41 | 2.39 | 2.55 | 3.73 | |
Average Days of Payables |
39.37 | 17.91 | 40.80 | 40.42 | |
Days of Inventory on Hand |
175.97 | 183.35 | 177.32 | 184.57 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
32.70% | 34.07% | 34.70% | 38.24% | |
Selling, General and Administrative Expense of Revenue |
95.36% | 93.21% | 92.20% | 93.72% | |
Share Based Compensation of Revenue |
17.82% | 17.22% | 16.34% | 15.39% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.76 | 0.82 | 0.70 | 0.73 | |
Depreciation/Fixed assets |
0.52 | 0.32 | 0.33 | 0.33 | |
Capex/Depreciation |
(50.11) | (86.89) | (98.10) | (1.60) | |
Revenue per Share |
2.67 | 2.48 | 2.47 | 2.03 | |
Operating CF per Share |
(1.25) | (1.23) | (1.26) | (1.30) | |
Capex per Share |
(6.34) | (6.37) | (6.96) | (0.09) | |
Capex to Sales |
2.37 | 2.57 | 2.81 | 0.04 | |
Net Profit Margin |
(61.32%) | (60.27%) | (73.02%) | (87.89%) |
Columns are period end dates